Srilatha Vuthoori Ms

Srilatha Vuthoori, MS, PMP has a strong background in pharmaceutical and biotech companies, with experience in various roles related to drug development, portfolio management, and clinical operations.

Srilatha started their career at the National Institutes of Health as a Pre-Doctoral Intramural Research Award Training Fellow, where they studied initial transcriptional events after bacteriophage-T4 infection of E. coli.

Srilatha then joined Regeneron Pharmaceuticals, where they served as a Program Coordinator and later as a Project Manager. In these roles, they were involved in the development of aflibercept, a potent angiogenesis inhibitor, for oncology and ophthalmology indications. Srilatha managed cross-functional phase I-III drug development programs and supervised preclinical studies to support clinical development.

Following their time at Regeneron Pharmaceuticals, they worked at Allergan Pharmaceuticals as a Principal Clinical Research Associate and later as a Clinical Study Manager. In these positions, they managed Phase 3 clinical studies, evaluated and selected study sites, and wrote and reviewed trial documents.

Srilatha then joined Centers for Therapeutic Innovation (CTI) New York - Pfizer as a Project Manager, where they managed multiple programs in early R&D stages in collaboration with project team leaders and academic medical centers.

After that, they worked at Mesoblast as a Clinical Operations Leader, where they oversaw clinical research organization (CRO) cross-functional study teams and ensured the execution of remestemcel-L and rexlemestrocel-L studies in various indications.

Srilatha then moved to IMMUNE Pharmaceuticals Inc. as an Executive Director of R&D Project Management, where they played a key role in managing and overseeing R&D projects.

Prior to their current role, they worked at Sellas Life Sciences as an Executive Director of Portfolio Management, where they ensured executional excellence, operational efficiency, and timely delivery of programs. Srilatha also established strategic alliances and managed alliance partnerships.

Currently, they are the Vice President of Drug Development Portfolio Management at Moleculin Biotech, Inc. In this role, they are responsible for the execution of dynamic cross-functional life-cycle program strategy and development. Srilatha drives program operations, strategy, and portfolio prioritization and builds strong relationships with key stakeholders.

Throughout their career, Srilatha Vuthoori has demonstrated strong leadership, collaborative skills, and expertise in program management, drug development, and clinical operations.

Srilatha Vuthoori, MS, PMP attended the University of Delaware from 1993 to 1997, where they obtained a Bachelor of Science degree in Biological Sciences with a concentration in Biotechnology. From 1998 to 2000, they pursued their Master of Science degree at New York University, specifically in the Molecular Oncology and Tumor Immunology Training Program (formerly Pathology Training Program). In 2013, they obtained their Project Management Certification, PMP, from the Project Management Institute.